These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 12244784

  • 21. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
    Cozzani M, Giovannini I, Naccari R, Penolazzi L, Lambertini E, Borgatti M, Piva R, Gambari R, Siciliani G.
    Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
    [No Abstract] [Full Text] [Related]

  • 22. Regulation of bone cell development and function: implication for renal osteodystrophy.
    Disthabanchong S, González EA.
    J Investig Med; 2001 May; 49(3):240-9. PubMed ID: 11352181
    [No Abstract] [Full Text] [Related]

  • 23. [Osteoporosis].
    Chaki O.
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():370-4. PubMed ID: 16689336
    [No Abstract] [Full Text] [Related]

  • 24. The role of the immune system in the pathophysiology of osteoporosis.
    Clowes JA, Riggs BL, Khosla S.
    Immunol Rev; 2005 Dec; 208():207-27. PubMed ID: 16313351
    [Abstract] [Full Text] [Related]

  • 25. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
    Kostenuik PJ.
    Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
    [Abstract] [Full Text] [Related]

  • 26. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N, Colla S, Rizzoli V.
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [Abstract] [Full Text] [Related]

  • 27. Osteoprotegerin, RANK, RANKL.
    Stejskal D, Bartek J, Pastorková R, Růzicka V, Oral I, Horalík D.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):61-4. PubMed ID: 12426773
    [Abstract] [Full Text] [Related]

  • 28. A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders.
    Juji T, Hertz M, Aoki K, Horie D, Ohya K, Gautam A, Mouritsen S, Oda H, Nakamura K, Tanaka S.
    J Bone Miner Metab; 2002 Dec; 20(5):266-8. PubMed ID: 12203031
    [No Abstract] [Full Text] [Related]

  • 29. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B.
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [Abstract] [Full Text] [Related]

  • 30. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
    Blair JM, Zhou H, Seibel MJ, Dunstan CR.
    Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
    [Abstract] [Full Text] [Related]

  • 31. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.
    Zehnder AF, Kristiansen AG, Adams JC, Merchant SN, McKenna MJ.
    Laryngoscope; 2005 Jan; 115(1):172-7. PubMed ID: 15630389
    [Abstract] [Full Text] [Related]

  • 32. Genetic regulation of osteoclast development and function.
    Teitelbaum SL, Ross FP.
    Nat Rev Genet; 2003 Aug; 4(8):638-49. PubMed ID: 12897775
    [Abstract] [Full Text] [Related]

  • 33. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A, Data V, Angeli A.
    J Endocrinol Invest; 2005 Aug; 28(10 Suppl):14-22. PubMed ID: 16550717
    [Abstract] [Full Text] [Related]

  • 34. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.
    Zhonghua Yi Xue Za Zhi; 2004 Dec 17; 84(24):2102-6. PubMed ID: 15730627
    [Abstract] [Full Text] [Related]

  • 35. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
    Hofbauer LC, Schoppet M.
    JAMA; 2004 Jul 28; 292(4):490-5. PubMed ID: 15280347
    [Abstract] [Full Text] [Related]

  • 36. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF, Bijlsma JW.
    Ned Tijdschr Geneeskd; 2005 Jul 23; 149(30):1664-7. PubMed ID: 16104110
    [Abstract] [Full Text] [Related]

  • 37. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
    Tian QX, Huang GY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug 23; 26(4):418-22. PubMed ID: 15379268
    [Abstract] [Full Text] [Related]

  • 38. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
    Hofbauer LC.
    Ann Endocrinol (Paris); 2006 Apr 23; 67(2):139-41. PubMed ID: 16639364
    [No Abstract] [Full Text] [Related]

  • 39. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N, Colla S, Rizzoli V.
    Acta Biomed; 2004 Dec 23; 75(3):143-52. PubMed ID: 15796087
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.